Scalper1 News
Good clinical-trial news rolled in for leading drugmakers Wednesday, helping to buoy the group’s recovery on the stock market. Big pharma Pfizer (PFE) said early Wednesday that it had stopped a phase-three trial of its drug Ibrance early because it had already hit its endpoint in patients with metastatic breast cancer. Ibrance was FDA-approved in February based on a similarly successful trial combining it with Novartis ‘ (NVS) Femara as a Scalper1 News
Scalper1 News